Recently, there is an emerging paradigm that DNA damage, which frequently occurs in cancer cells, leads to the expression of interferon and chemokines activating immune cells in the tumor microenvironment [202]; therefore, immunotherapy combined with drugs inhibiting DNA-repair proteins is now one of the most promising therapies. Here, PROS1 is linked to neoplasm.